ES2085297T3 - Procedimiento para preparar derivados de poli(etilenglicol) y proteina modificada. - Google Patents

Procedimiento para preparar derivados de poli(etilenglicol) y proteina modificada.

Info

Publication number
ES2085297T3
ES2085297T3 ES90109806T ES90109806T ES2085297T3 ES 2085297 T3 ES2085297 T3 ES 2085297T3 ES 90109806 T ES90109806 T ES 90109806T ES 90109806 T ES90109806 T ES 90109806T ES 2085297 T3 ES2085297 T3 ES 2085297T3
Authority
ES
Spain
Prior art keywords
modified protein
poly
procedure
ethylene glycol
preparing derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90109806T
Other languages
English (en)
Inventor
Keiichi Ono
Yoshiyuki Kai
Yoshiharu Ikeda
Hiroo Maeda
Katsukiyo Sakurai
Yoshikatsu Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharmaceuticals Co Ltd
Seikagaku Corp
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Seikagaku Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd, Seikagaku Corp filed Critical Sumitomo Pharmaceuticals Co Ltd
Application granted granted Critical
Publication of ES2085297T3 publication Critical patent/ES2085297T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DERIVADOS DE ETILENO GLICOL DE ALTA PUREZA DE FORMULA (I) SE USAN COMO MODIFICADORES DE PROTEINA DE INTERFERONES, T-PA, EGF, VARIAS HORMONAS,ETC. LAS PROTEINAS MODIFICADAS DE ESTE MODO TIENEN ANTIGENICIDAD MINIMIZADA, PROLONGADA SEMI-VIDA PARA EL PLASMA, O TRANSFERENCIA MEJORADA PARA TEJIDOS. TAMBIEN SE DESCUBRE UN NUEVO PROCESO PARA PREPARAR DERIVADOS DE POLIETILENO GLICOL DE ALTA PUREZA.
ES90109806T 1989-05-27 1990-05-23 Procedimiento para preparar derivados de poli(etilenglicol) y proteina modificada. Expired - Lifetime ES2085297T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13419189 1989-05-27
JP13419289 1989-05-27

Publications (1)

Publication Number Publication Date
ES2085297T3 true ES2085297T3 (es) 1996-06-01

Family

ID=26468359

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90109806T Expired - Lifetime ES2085297T3 (es) 1989-05-27 1990-05-23 Procedimiento para preparar derivados de poli(etilenglicol) y proteina modificada.

Country Status (7)

Country Link
EP (1) EP0400472B1 (es)
AT (1) ATE136315T1 (es)
CA (1) CA2017543A1 (es)
DE (1) DE69026306T2 (es)
DK (1) DK0400472T3 (es)
ES (1) ES2085297T3 (es)
GR (1) GR3019991T3 (es)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2675807B1 (fr) * 1991-04-23 1994-07-01 Medgenix Group Sa Conjugue de calcitonine et de polyethylene glycol.
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
RO121474B1 (ro) 1997-06-06 2007-06-29 Kyowa Hakko Kogyo Co., Ltd. Polipeptide modificate chimic
EP0922446A1 (en) * 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
WO2001051510A2 (en) 2000-01-10 2001-07-19 Maxygen Holdings Ltd G-csf conjugates
JP2003521930A (ja) 2000-02-11 2003-07-22 マキシゲン・エイピーエス 第ＶＩＩ因子または第ＶＩＩａ因子様分子
US6881789B2 (en) * 2000-05-30 2005-04-19 Viridis Biotech Inc. Polyubiquitin based hydrogel and uses thereof
CZ20032526A3 (cs) 2001-02-27 2003-12-17 Maxygen Aps Nové molekuly podobné interferonu beta
AU2002303869B2 (en) 2001-05-21 2007-08-16 Novartis Ag Pulmonary administration of chemically modified insulin
EP1517710B1 (en) 2002-06-21 2011-03-30 Novo Nordisk Health Care AG Pegylated factor vii glycoforms
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
ATE448323T1 (de) 2003-03-05 2009-11-15 Halozyme Inc Lösliches hyaluronidase-glycoprotein (shasegp), verfahren zu seiner herstellung, verwendungen und dieses enthaltende pharmazeutische zusammensetzungen
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2004084949A2 (en) * 2003-03-20 2004-10-07 Xencor Generating protein pro-drugs using reversible ppg linkages
MXPA05012313A (es) 2003-05-12 2006-04-18 Affymax Inc Peptidos que se unen al receptor de eritropoyetina.
DK1629007T3 (da) 2003-05-12 2009-06-29 Affymax Inc Hidtil ukendte peptider som binder til erythropoietin-receptoren
NZ543934A (en) 2003-05-12 2008-06-30 Affymax Inc Novel spacer moiety for poly (ethylene glycol)-modified peptide-based compounds
EP1626983B8 (en) * 2003-05-12 2010-12-22 Affymax, Inc. Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof
CN102516386A (zh) 2003-10-10 2012-06-27 诺沃挪第克公司 Il-21衍生物
EP2633866A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
CN103755800B (zh) 2004-02-02 2016-02-24 Ambrx公司 经修饰的人类生长激素多肽与其用途
JP2008502788A (ja) 2004-06-08 2008-01-31 アルザ コーポレイション ４成分縮合反応による高分子コンジュゲートの調製
BRPI0512235A (pt) 2004-06-18 2008-02-19 Ambrx Inc polipeptìdeos ligadores de antìgenos e seus usos
MX2007000568A (es) * 2004-07-16 2007-03-30 Nektar Therapeutics Al Corp Conjugados de una fraccion gm-csf y un polimero.
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
CN103690936A (zh) 2004-12-22 2014-04-02 Ambrx公司 经修饰的人类生长激素
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
JP2009520949A (ja) 2005-11-16 2009-05-28 アンブルックス，インコーポレイテッド 非天然アミノ酸を含んでいる組成物および方法
JP2009537609A (ja) 2006-05-24 2009-10-29 ノボ ノルディスク ヘルス ケア アーゲー 延長されたｆｉｘアナログ及び誘導体
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
US8552158B2 (en) 2006-08-31 2013-10-08 Hoffmann-La Roche Inc. Method for the production of insulin-like growth factor-1
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
MX2010008632A (es) 2008-02-08 2010-08-30 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
EP2318029B1 (en) 2008-07-23 2017-11-01 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
CA2737040C (en) * 2008-09-19 2017-05-02 Nektar Therapeutics Polymer conjugates of therapeutic peptides
US20110171161A1 (en) 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of protegrin peptides
EP2334334A1 (en) 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of nesiritide peptides
CA2738033C (en) 2008-09-26 2019-11-26 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
KR101647164B1 (ko) 2008-09-26 2016-08-09 암브룩스, 인코포레이티드 변형된 동물 에리트로포이에틴 폴리펩티드 및 이의 용도
RS58728B1 (sr) 2008-12-09 2019-06-28 Halozyme Inc Produženi rastvorljivi ph20 polipeptidi i njihove upotrebe
CN102666578A (zh) 2009-12-21 2012-09-12 Ambrx公司 经过修饰的猪促生长素多肽和其用途
PE20121707A1 (es) 2009-12-21 2012-12-17 Ambrx Inc Polipeptidos de somatotropina bovina modificados y sus usos
WO2011107591A1 (en) 2010-03-05 2011-09-09 Rigshospitalet Chimeric inhibitor molecules of complement activation
EP2569331A1 (en) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptide inhibitors of vla4
DK2595624T3 (en) 2010-07-20 2018-03-26 Halozyme Inc Methods of treating or preventing adverse side effects associated with administration of an anti-hyaluronan agent
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
RS59193B1 (sr) 2010-08-17 2019-10-31 Ambrx Inc Modifikovani polipeptidi relaksina i njihova primena
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
WO2013004607A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
MX342735B (es) 2011-10-24 2016-10-07 Halozyme Inc Diagnostico acompañante para terapia con agente anti-hialuronano y metodos de uso del mismo.
BR112014016195A2 (pt) 2011-12-30 2020-10-27 Halozyme, Inc. variantes de polipeptídio ph20, formulações e usos das mesmas
JP6042527B2 (ja) 2012-04-04 2016-12-14 ハロザイム インコーポレイテッド 抗ヒアルロナン剤と腫瘍標的タキサンの組み合わせ治療
CN104583235B (zh) 2012-06-08 2019-03-01 苏特罗生物制药公司 含位点特异非天然氨基酸残基的抗体、其制备和使用方法
US9732161B2 (en) 2012-06-26 2017-08-15 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
ES2907763T3 (es) 2012-08-31 2022-04-26 Sutro Biopharma Inc Aminoácidos modificados que comprenden un grupo azido
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
TR201907471T4 (tr) 2014-08-28 2019-06-21 Halozyme Inc Bir hiyalüronan ayrıştırıcı enzim ve bir bağışıklık kontrol noktası inhibitörüyle kombinasyon terapisi.
TW202124419A (zh) 2014-10-24 2021-07-01 美商必治妥美雅史谷比公司 經修飾之fgf-21多肽及其用途
WO2018148419A1 (en) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
AU2019337610A1 (en) 2018-09-11 2021-05-06 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
AU2019361206A1 (en) 2018-10-19 2021-06-03 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
MX2021009644A (es) 2019-02-12 2021-09-08 Ambrx Inc Composiciones que contienen, metodos y usos de conjugados de anticuerpo-agonista de tlr.
JP2023517595A (ja) 2020-03-11 2023-04-26 アンブルックス，インコーポレイテッド インターロイキン－２ポリペプチド結合物およびその使用方法
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
IL307282A (en) 2021-04-03 2023-11-01 Ambrx Inc Antidote conjugates against HER2 and their applications

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60156395A (ja) * 1984-01-17 1985-08-16 Mihama Hisaharu 修飾リパーゼ
ES8800982A1 (es) * 1985-07-05 1987-12-01 Takeda Chemical Industries Ltd Un metodo para producir la enzima superoxido-dismutasa modificada con derivados de polietilenglicol y triazina.

Also Published As

Publication number Publication date
ATE136315T1 (de) 1996-04-15
CA2017543A1 (en) 1990-11-27
DE69026306T2 (de) 1996-10-17
EP0400472A3 (en) 1991-06-26
EP0400472A2 (en) 1990-12-05
DE69026306D1 (de) 1996-05-09
DK0400472T3 (da) 1996-05-13
EP0400472B1 (en) 1996-04-03
GR3019991T3 (en) 1996-08-31

Similar Documents

Publication Publication Date Title
ES2085297T3 (es) Procedimiento para preparar derivados de poli(etilenglicol) y proteina modificada.
ES2040261T3 (es) Procedimiento para preparar acidos 6-fluor-4-oxo-1,4-dihidroquinolina-3-carboxilicos sustituidos y acidos 9-fluor-3-metil-7-oxo-2,3-dihidro-7h-pirido(1,2,3-de)(1,4)benzoxazina-6-carboxilico sustituidos.
PH31617A (en) Novel thienylcarboxylates of amino alcohols, theirquaternary products and use of these compounds.
ES2124373T3 (es) Procedimiento para la preparacion de derivados del acido n-acil-n,n',n'-etilendiamintriacetico.
DK0409435T3 (da) Heteroarylpiperaziner som antipsykotiske midler
HUT49113A (en) Process for producing 2-/2-hydroxy-3-phenoxy-propyl-amino/-ethyl-phenoxy-methyl-amido derivatives and pharmaceutical compositions containing them as active components
FI905475A0 (fi) Menetelmä farmaseuttisesti vaikuttavan puriinijohdannaisen valmistamiseksi
FI860842A (fi) Labdan-derivat, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
MX17846A (es) Proceso para la preparacion de nuevos derivados de 9h purina.
FI893842A0 (fi) Menetelmä uuden antibiootin, mersasidiinin, valmistamiseksi
ES545194A0 (es) Un procedimiento para preparar derivados de purina
DE58905079D1 (de) Neue alpha-aminocarbonsaeure-derivate, ihre herstellung und verwendung.
ES528365A0 (es) Compuestos de cromano
ES2032427T3 (es) Procedimiento para producir derivados de 2,5,6,7-tetranor-18,18,19,19-tetradeshidro-4,8-inter-m-fenileno-pgi2. (reserva del art. 167.2 cpe).
DE3751586D1 (de) Antitumor-Aminosäuren und Peptid-Derivate von 1,4-bis[(Aminoalkyl und Hydroxyaminoalkyl)amino]5,8-Dihydroxyanthraquinonen.
ES2032407T3 (es) Procedimiento para preparar 1,3-dioxenonas opticamente puras. (reserva del art. 167.2 cpe).
YU6087A (en) Process for obtaining 2-benzimidazole-ilalkylthiosulphinyl or sulphonyl derivatives
NO901176D0 (no) Fremgangsmaate for fremstilling av 2,5,6,7-tetranor-4,8-inter-m-fenylen pgi2-derivater.
ATE132500T1 (de) 24r-scymnol, herstellung und verwendung
AU4034095A (en) Cyclohexapeptides and their mixtures, a process for preparing them, and their use
HUT71512A (en) N-(3-chlorophenyl)-piperazine derivatives for producing alkyl-trazodon derivatives and process for producing them
ES2033256T3 (es) Procedimiento para preparar derivados fluorados de la vitamina d3.
NO174963C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 8-fluorantracyklinglucosider
FI944907A0 (fi) Uusi antineoplastinen sytokiini
ES2134971T3 (es) Derivado de acido octahidro-2-naftaleno-carboxilico, su produccion y uso.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 400472

Country of ref document: ES